Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»Business

    Eli Lilly to acquire Centessa and sleep disorder drugs

    AdminBy AdminMarch 31, 2026 Business
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    Eli Lilly to acquire Centessa and sleep disorder drugs

    Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Texas, Sept. 23, 2025.

    Antranik Tavitian | Reuters

    Eli Lilly has agreed to pay up to $7.8 billion to acquire Centessa Pharmaceuticals and its experimental drug for excessive daytime sleepiness, the company said Tuesday.

    Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for people to stay awake during the day. The drugs may also be used to treat other neurological conditions that are accompanied by drowsiness, such as Alzheimer’s disease and depression, and possibly even more broadly.

    Other possibilities include another severe sleep disorder called idiosyncratic hypersomnia, as well as other conditions where people experience sleepiness or executive function problems during the day and poor sleep at night, Lilly CEO Dave Ricks said in an interview with CNBC.

    “We see a broader potential for this pathway, maybe a little bit of analogy to GLP-1, in a way that you know sleep and wakefulness are like core to our functioning, and when your sleep is disturbed or your wakefulness is disturbed, it causes a problem,” Ricks said. “So I think you can count on Lilly exploring broad use for the orexins and this new pathway, and we’re pretty excited about it.”

    Under the terms of the deal, Lilly will pay $38 a share up front, or $6.3 billion for Centessa, a 38% premium to Monday’s closing price. If Centessa’s drugs win approval by the U.S. Food and Drug Administration by certain deadlines, Lilly will pay up to another $1.5 billion.

    The transaction is expected to close in the third quarter, pending regulatory approval.

    Shares of Lilly rose roughly 3% Tuesday, while Centessa’s stock surged 45%.

    Orexin agonists used to treat narcolepsy and another severe sleep condition, called idiopathic hypersomnia, could amount to a $15 billion to $20 billion market if even about one quarter of patients seek treatment, according to an estimate from Oppenheimer analyst Kostas Biliouris. Sales could go even higher if the drugs are used more broadly.

    Centessa won’t be the first to market with its orexin agonist. A rival drug from Takeda is under review with the FDA and could be approved later this year.

    Biliouris said he doesn’t expect Centessa’s drug to be approved until 2028, but he sees signs from mid-stage trial data that Centessa’s treatment could become the best in class.

    Lilly, for its part, is a longtime leader in neuroscience. The company’s antidepressant Prozac catapulted Lilly to the top ranks of the pharmaceutical industry after it was approved in 1987.

    More recently, Lilly introduced a drug called Kisunla for the early stages of Alzheimer’s disease with another trial on the horizon to see if the treatment can prevent the memory-robbing disease.

    Lilly has been vocal about its intention to use the cash coming from its best-selling obesity and diabetes drugs Zepbound and Mounjaro to place more bets. Already this year, Lilly announced its intention to acquire cell-therapy company Orna Therapeutics and inflammation-focused Ventyx Biosciences.

    Of the Centessa deal, Ricks said, “It’s the kind of thing we should be doing to really affect millions and millions of people, potentially, who suffer from neuroscience conditions like wakefulness and sleep.”

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Anthropic prices IPO at $83 a share, blowing past target range: report

    November 19, 2026

    California DMV boots Waymo robotaxis off state freeways after string of incidents

    November 18, 2026

    Chipotle launches Sneak It In hoodies with hidden pouch to keep your burrito warm

    November 17, 2026

    Big-ticket holiday items may be harder to find as shipping costs rise

    November 16, 2026

    Jensen Huang weighs Nvidia CEO comeback as ally plans war room: report

    November 16, 2026

    New Orleans port seeks tanker seizure after cruise ship crash sparks $1M lawsuit

    November 15, 2026
    Popular Posts

    How to tell a cyberattack from a plain old outage

    Movie Review: Elsinore

    Interview with Aletheia von Gottlieb, Author of Love Off the Ice (Sweet Snowfall Kisses Book 1) – NewInBooks

    What Were Wearing: Friendsgiving

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    Book Riots Deals of the Day for November 18, 2026

    Categories
    • Books (2,457)
    • Business (3,449)
    • Events (34)
    • Film (1,062)
    • LifeStyle (2,922)
    • Music (2,796)
    • Politics (2,355)
    • Science (1,952)
    • Technology (1,817)
    • Television (3,628)
    • US News (3,294)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • AI revolution is ‘50x bigger’ than dot-com boom: SoftBank’s Masayoshi SonAI revolution is ‘50x bigger’ than dot-com boom: SoftBank’s Masayoshi Son
    • 10-year Treasury yield climbs above 4.2% after Fed commentary10-year Treasury yield climbs above 4.2% after Fed commentary
    • California is overhauling its autonomous vehicle regulationsCalifornia is overhauling its autonomous vehicle regulations
    • A list of upcoming Kpop concerts, tours and music festivals in AsiaA list of upcoming Kpop concerts, tours and music festivals in Asia
    • Would You Buy Diamonds Grown on Demand?
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.